Abbott Laboratories (ABT) Stock Price & Analysis
Abbott Laboratories (ABT) closed at USD 102.51 on Thursday, October 22, 2026, up 1.99% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 102.51; the Oct 22, 2026 session ranged USD 99.95–102.9 on volume of 10,649,514 shares. Market capitalization is —, with a 52-week range of USD 81.97–132.03 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ABT.md
Key facts (ABT)
- Last four reported quarters (through Jun 30, 2026): revenue $46.6B, net income $5.42B (11.6% margin), free cash flow $7.82B (SEC filings).
- 7 of 80 tracked superinvestors hold ABT (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 1 new, 2 added, 2 reduced, 2 unchanged.
- Analysts: Buy (mean 1.96 on a 1–5 scale) (28 analysts), mean target USD 118.6 (range 103–130).
- Total return with dividends: 1Y -16.9% vs S&P 500 +14.9%; 5Y -10.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-21, EPS estimate USD 1.64, revenue estimate $13.2B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ABT)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B | $46.6B |
| Gross profit | $24.5B | $24.5B | $22.1B | $23.2B | $25.0B | — |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B | $7.35B |
| Net income | $7.07B | $6.93B | $5.72B | $13.4B | $6.52B | $5.42B |
| EPS (diluted) | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | — |
| Free cash flow | $8.65B | $7.80B | $5.06B | $6.35B | $7.39B | $7.82B |
| Gross margin | 57.0% | 56.1% | 55.2% | 55.4% | 56.4% | — |
| Operating margin | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% | 15.8% |
| Net margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% | 11.6% |
| Revenue growth | +24.5% | +1.3% | -8.1% | +4.6% | +5.7% | — |
| Cash + short-term investments | $10.2B | $10.2B | $7.28B | $7.97B | $8.94B | — |
| Total debt | $18.1B | $16.8B | $14.7B | $14.1B | $12.9B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ABT)
P/E at fiscal year-ends: Dec 2025 33.6x, Dec 2024 14.8x, Dec 2023 33.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (ABT)
7 of 80 tracked investors hold ABT (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Mason Hawkins | Southeastern Asset Management | 3.98% | $76.3M | New position | Q2 2026 |
| Jensen Investment Management | 1.95% | $80.3M | Reduced -40.4% | Q2 2026 | |
| Mairs & Power | Mairs & Power Funds | 0.61% | $66.2M | Added +1.1% | Q2 2026 |
| David Katz | Matrix Asset Advisors | 0.43% | $5.2M | Added +11.7% | Q3 2026 |
| Thomas Russo | Gardner Russo & Quinn | 0.01% | $1.0M | Unchanged | Q2 2026 |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $1.6M | Unchanged | Q2 2026 |
| Polen Capital | Polen Capital Management | <0.01% | $286K | Reduced -79.1% | Q2 2026 |
Analysts (ABT)
Consensus Buy (mean 1.96 on a 1–5 scale), 28 analysts; mean target USD 118.6 (low 103, high 130).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | Citigroup | Target lowered | Buy | $125 → $122 |
| 2026-10-22 | RBC Capital | Target lowered | Outperform | $130 → $125 |
| 2026-10-22 | Wells Fargo | Target raised | Overweight | $112 → $119 |
| 2026-10-22 | JP Morgan | Target lowered | Overweight | $120 → $118 |
| 2026-10-22 | TD Cowen | Target lowered | Buy | $135 → $118 |
| 2026-10-22 | Baird | Target raised | Outperform | $121 → $123 |
| 2026-10-22 | BTIG | Target lowered | Buy | $134 → $125 |
| 2026-10-16 | TD Cowen | Reiterated | Buy | $135 |
| 2026-10-07 | Barclays | Initiated | Overweight | $120 |
| 2026-10-02 | Rothschild & Co | Upgrade | Neutral → Buy | $119 → $127 |
| 2026-09-08 | TD Cowen | Reiterated | Buy | $135 |
| 2026-08-25 | TD Cowen | Target raised | Buy | $115 → $135 |
Total return (dividends reinvested) (ABT)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -16.9% | -10.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -16.9% | -2.2% |
| Volatility (annualized) | 27.4% | 23.1% |
| Max drawdown | -36.1% (Nov 2025→May 2026) | -37.4% (Feb 2025→May 2026) |
ABT revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Medical Devices | $5.85B | 46.5% | +9.0% |
| Diagnostic Products | $3.09B | 24.6% | +42.3% |
| Nutritional Products | $2.14B | 17.0% | -3.1% |
| Established Pharmaceuticals | $1.50B | 11.9% | +8.4% |
| Total revenue | $12.59B | 100% | — |
ABT revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| International | $7.38B | 58.6% | +7.4% |
| United States | $5.22B | 41.4% | +22.0% |
| Total revenue | $12.59B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
Companies that name ABT in their SEC reports
| Relationship to ABT | Company | Filing | Sentence |
|---|---|---|---|
| partner | MATERIALISE NV (MTLS) | 20-F Apr 23, 2026 | “In the medical market, we have entered into collaborations with DePuy Synthes Companies of Johnson & Johnson, or DePuy Synthes, and Zimmer Biomet Holdings, Inc., or Zimmer Biomet, as well as with Encore Medical, L.P. (d/b/a Enovis), or Enovis, Limacorporate Spa, or Lima, Mathys AG, or Mathys (which is now part of the same company as Enovis), Smith & Nephew Inc., or Smith & Nephew, Corin Ltd, or Corin, Medtronic In…” |
| partner | 20/20 Biolabs, Inc. (AIDX) | 10-K Mar 31, 2026 | “September 29, 2022, the Company entered into a lease agreement with Abbott Laboratories, Inc. for laboratory equipment (analyzer).” |
ABT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $1.64 | $1.64 | +0.2% | $13.20B | 23 |
| Next quarter (ends Mar 2027) | $1.26 | $1.29 | -2.3% | $12.67B | 17 |
| Current fiscal year (ends Dec 2026) | $5.52 | $5.51 | +0.1% | $49.90B | 26 |
| Next fiscal year (ends Dec 2027) | $5.99 | $6.06 | -1.3% | $53.91B | 27 |
ABT options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 29.4% | ±3.5% |
| Nov 6, 2026 | 14 | 29.8% | ±4.9% |
| Nov 13, 2026 | 21 | 29.9% | ±5.9% |
| Nov 20, 2026 | 28 | 26.7% | ±6.0% |
| Nov 27, 2026 | 35 | 26.4% | ±6.6% |
| Dec 4, 2026 | 42 | 28.2% | ±7.8% |
| Dec 18, 2026 | 56 | 26.2% | ±8.5% |
| Jan 15, 2027 | 84 | 25.7% | ±10.3% |
30-day implied volatility 26.6% vs 21.3% realized over the last 30 trading days. Put/call ratio (volume) 0.75. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 102.51 |
|---|---|
| Change | ▲ 1.99% (up) |
| Previous Close | USD 102.51 |
| Open | USD 102.51 |
| Day Range | USD 99.95 – 102.9 |
| 52-Week Range | USD 81.97 – 132.03 |
| Volume | 10,649,514 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (ABT)
Nexqual's technical model rates ABT "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.33 (neutral) |
| vs SMA50 | Below (USD 105.32) |
| MACD | -0.21 (negative) |
Analyst Ratings (ABT)
Wall Street analysts rate ABT "Buy" based on 28 analysts, with a mean price target of USD 118.6 (range USD 103–130), per Nexqual as of October 23, 2026 at 09:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 28 |
| Mean Target | USD 118.6 |
| High Target | USD 130 |
| Low Target | USD 103 |
| Buy / Hold / Sell | 24 / 4 / 0 |
Earnings (ABT)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 1.64 |
| Revenue Estimate | $13.20B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 1.42 vs est 1.41 ▲ beat |
| 2026-06-30 | USD 1.31 vs est 1.28 ▲ beat |
| 2026-03-31 | USD 1.15 vs est 1.15 ▲ beat |
| 2025-12-31 | USD 1.5 vs est 1.49 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (ABT)
| Total Revenue | $48.23B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +14.50% |
| Gross Margin | +57.17% |
| Operating Margin | +10.44% |
| Profit Margin | +9.75% |
| Debt / Equity | 0.63 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $7.82B (16.8% of revenue) |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financial Health Score (ABT)
Nexqual rates Abbott Laboratories's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:21 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 10% (last 12 months) |
| Balance Sheet | Solid — $5.60B cash and investments vs $32.6B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $7.82B (last 4 quarters to Jun 2026, SEC), 17% margin |
| Efficiency | Mixed — No data |
Ownership (ABT)
| Insider Ownership | +0.49% |
|---|---|
| Institutional Ownership | +81.84% |
| Shares Outstanding | 1.73B |
| Float | 1.72B |
| Short % of Float | +0.88% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
From Abbott Laboratories's Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services has issued rules governing the use, disclosure, and security of protected health information, and the FDA has issued further guidance concerning cybersecurity for medical devices.
Legal & Regulatory Risks (Item 1A, quoted)
- Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to change its business practices, and restrict its operations, which could result in a material adverse effect on Abbott's revenues, profitability, and financial condition.
- Changes in the healthcare regulatory environment may adversely impact the demand for and price of Abbott's products.
- The expiration or loss of intellectual property protection and licenses may affect Abbott's future revenues and operating earnings.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MDT | Medtronic plc. | USD 96.59 | ▲ 3.83% |
| SYK | Stryker Corporation | USD 307.08 | ▲ 3.19% |
| BSX | Boston Scientific Corporation | USD 46.01 | ▲ 3.37% |
| EW | Edwards Lifesciences Corporatio | USD 90.09 | ▲ 1.91% |
| GEHC | GE HealthCare Technologies Inc. | USD 71.42 | ▲ 3.49% |
| DXCM | DexCom, Inc. | USD 78.32 | ▼ 2.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt